The American College of Physicians (ACP) issued its final update of living, rapid practice points on antiviral treatment for COVID‑19 in outpatient settings.
Using evidence from an updated rapid review focused on the Omicron variant, ACP reaffirms its earlier guidance for treating symptomatic, confirmed COVID‑19 in both vaccinated and unvaccinated patients.
The update is published in Annals of Internal Medicine.
The recommendations emphasize that nirmatrelvir–ritonavir and molnupiravir may be used for high‑risk patients with mild to moderate COVID‑19 if started within five days of symptom onset.
ACP advises against using ivermectin or sotrovimab, as evidence does not support their benefit in the outpatient setting.
Because recent updates and ongoing surveillance have not produced meaningful changes to these recommendations, ACP is retiring this topic from its “living” status, meaning it will no longer be continuously updated, according to the organization.
